Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604703 | 0.88 | HDAC1 (0.63) | AAK1HDAC1HDAC2HDAC3GPR35 | |
| SCHEMBL17493733 | 0.85 | AAK1 (1.00) | AAK1HDAC1HDAC2HDAC3GAA | |
| SCHEMBL18508243 | 0.85 | AAK1 (0.59) | AAK1HDAC1HDAC2HDAC3KMT2A | |
| SCHEMBL15111081 | 0.84 | AAK1 (0.61) | AAK1HDAC1HDAC2HDAC3KMT2A | |
| SCHEMBL8339616 | 0.82 | AAK1 (0.53) | AAK1HDAC1HDAC2HDAC3GAA | |
| SCHEMBL25151822 | 0.81 | HTT (0.52) | AAK1HDAC1HDAC2HDAC3GAA | |
| SCHEMBL17493751 | 0.79 | AAK1 (0.57) | AAK1HDAC1HDAC2HDAC3GAA | |
| SCHEMBL17493705 | 0.78 | AAK1 (1.00) | AAK1KMT2AALDH1A1 | |
| SCHEMBL15594368 | 0.78 | KMT2A (0.68) | AAK1GAAKMT2AALDH1A1 | |
| SCHEMBL18664787 | 0.78 | ALDH1A1 (0.60) | AAK1HDAC1HDAC2HDAC3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | SLC10A1, CYP2C9, UGT1A9 | AAK1 1985/4885HDAC1 969/4885HDAC2 2380/4885 |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | AAK1 3794/4885HDAC1 1019/4885HDAC2 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.